StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc. (REGN) stock

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/308% above fair value
$955.47+4.28 (+0.45%)

Close on Nov 13, 2026Market cap $98.84BP/E 21.1Yield –

Regeneron Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Regeneron Pharmaceuticals's price to sales ratio was 6.6× on Nov 11, 2026, against 6.0× a year earlier. Over the last 5 years it ranged from 4.0× to 10.0×, with a median of 6.0×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20266.6×+0.7
2025Dec 31, 20256.0×+0.0
2024Dec 31, 20245.9×−1.7
2023Dec 29, 20237.6×+1.7
2022Dec 30, 20226.0×+0.7
2021Dec 31, 20215.2×−1.8
2020Dec 31, 20207.0×+0.5
2019Dec 31, 20196.5×−0.2
2018Dec 31, 20186.7×−1.2
2017Dec 29, 20177.9×−1.1
2016Dec 30, 20169.0×−7.4
2015Dec 31, 201516.4×−0.8
2014Dec 31, 201417.2×+0.3
2013Dec 31, 201316.9×+2.1
2012Dec 31, 201214.9×+3.9
2011Dec 30, 201111.0×+4.8
2010Dec 31, 20106.2×–

More Regeneron Pharmaceuticals figures

See a number that looks wrong?